| Literature DB >> 31379605 |
Danijela Vasić1,2, Marko Novaković3, Mojca Božič Mijovski4, Breda Barbič Žagar5, Borut Jug1,3.
Abstract
BACKGROUND: We hypothesized that a 2-week twice daily aquatic endurance plus calisthenics exercise training program: (i) increases aerobic exercise capacity (peak oxygen uptake/ V ˙ O2peak), (ii) improves endothelium-dependent flow-mediated vasodilation (FMD), and (iii) reduces circulating markers of low-grade inflammation and hemostasis, as compared to land-based endurance plus calisthenics exercise training or no exercise in patients undergoing short-term residential cardiac rehabilitation after a recent coronary artery disease (CAD) event.Entities:
Keywords: aquatic exercise; cardiac rehabilitation; coronary artery disease; exercise training; myocardial infarction
Year: 2019 PMID: 31379605 PMCID: PMC6646683 DOI: 10.3389/fphys.2019.00903
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Patient selection and study design flowchart.
Baseline characteristic of the patients who completed the study.
| Variables | Patients who completed the study ( | Land-exercise group (I) ( | Water-exercise group (II) ( | Control group (III) ( | |
|---|---|---|---|---|---|
| Age Mean(SD), years | 59.9 (8.2) | 62.4 (7.6) | 56.7 (8.4) | 60.6 (8.3) | 0.026 (I–II) |
| Gender m/f, | 69 (77.5)/20 (2.5) | 21 (70)/9 (30) | 24 (82.8)/5 (17.2) | 24 (80)/6 (20) | 0.464 |
| 0.523 | |||||
| MI + PCI | 60 (67.4) | 19 (63.3) | 17 (58.6) | 24 (80) | |
| PCI | 3 (3.4) | 1 (3.3) | 2 (6.9) | 0 (0) | |
| CABG | 9 (10.1) | 3 (10) | 3 (10.3) | 3 (10) | |
| MI + CABG | 17 (19.1) | 7 (23.3) | 7 (24.1) | 3 (19) | |
| HBP | 52 (58.4) | 18 (60) | 14 (48.3) | 20 (66.7) | 0.350 |
| Dyslipidemia | 65 (73) | 19 (63.3) | 22 (75.9) | 24 (80) | 0.318 |
| Family history | 53 (59.6) | 19 (63.3) | 18 (62.1) | 16 (53.3) | 0.692 |
| Obesity | 20 (22.5) | 6 (20) | 7 (24.1) | 7 (23.3) | 0.921 |
| DM | 15 (16.9) | 3 (10) | 5 (17.2) | 7 (23.3) | 0.385 |
| Low physical activity level | 44 (49.4) | 17 (56.7) | 15 (51.7) | 12 (40) | 0.415 |
| Smoking status | 48(53.9) | 15 (59) | 16 (55.2) | 17 (53.9) | 0.863 |
| Aspirin | 86 (96.6) | 29 (96.7) | 29 (100) | 28 (93.3) | 0.366 |
| β blockers | 76 (85.4) | 26 (86.7) | 24 (82.8) | 26 (86.7) | 0.887 |
| Statins | 79 (88.8) | 26 (86.7) | 26 (89.7) | 27 (90) | 0.906 |
| ACE/ARB | 72 (80.9) | 24 (80) | 22 (75.9) | 26 (86.7) | 0.566 |
FIGURE 2Changes in aerobic exercise capacity (O2peak) and flow-mediated dilatation (FMD) expressed on the logarithmic scale.
Measurements for the three study groups at baseline and after training, and between group differences.
| Variables | Land-exercise group (I) | Water-exercise group (II) | Control group (III) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | After | Δ% | Baseline | After | Δ% | Baseline | After | Δ% | |||||
| VO2 peak ml kg-1 min-1 | 13.1 (2.8) | 15.1 (3.2) | 15.3 | 0.001 | 14.6 (3.3) | 18.6 (3.9) | 27.4 | 0.001 | 16.6 (3.6) | 16.5 (3.8) | -0.6 | 0.775 | 0.001 |
| VO2 (L min-1) | 1.07 (0.27) | 1.25 (0.33) | 16.8 | <0.001 | 1.31 (0.34) | 1.67 (0.41) | 27.4 | <0.001 | 1.47 (0.38) | 1.45 (0.40) | -1.3 | 0.265 | <0.001 (all) |
| TTE (sec) | 605 (91) | 710 (128) | 17.3 | <0.001 | 710 (123) | 864 (158) | 21.6 | <0.001 | 796 (150) | 800 (145) | 0.5 | 0.493 | <0.001 (all) |
| RER | 1.10 (1.10–1.10) | 1.12 (1.1–1.16) | 1.8 | 0.001 | 1.10 (1.10–1.11) | 1.15 (1.10–1.19) | 4.5 | 0.001 | 1.10 (1.10–1.11) | 1.10 (1.10–1.13) | 0.0 | 0.026 | 0.026 (II vs. III) |
| Peak workload (Watt) | 70 (15) | 88 (21) | 25.7 | <0.001 | 88 (21) | 113 (26) | 28.4 | <0.001 | 103 (25) | 104 (24) | 0.9 | 0.755 | <0.001 (all) |
| FMD (%) | 5.5 (3.1–8.6) | 8.8 (5.3–11.4) | 37.7 | <0.001 | 7.2(4.0–8.7) | 9.2 (7.4–12.9) | 44.9 | <0.001 | 7.0 (3.7–8.6) | 6.4 (3.7–8.5) | -1.5 | 0.692 | <0.001 (I–III, II–III) |
| NMD (%) | 10.6 (7.0–13.3) | 11.1 (9.0–14.3) | 11.6 | <0.001 | 10.5 (8.5–14.0) | 11.4 (7.6–13.4) | 5.4 | 0.042 | 10.9 (6.0–13.4) | 11.6 (7.4–14.2) | 2.9 | 0.579 | 0.013 (I–III) |
| Fibrinogen g L-1 | 3.0 (3.0–3.4) | 3.2 (3.0–3.5) | 6.7 | 0.875 | 3.3 (3.0–3.9) | 3.0 (2.7–3.8) | -9.1 | 0.248 | 3.0 (2.7–3.4) | 3.0 (2.6–3.3) | 0.0 | 0.791 | 0.565 |
| D dimer μg L-1 | 625 (280–1220) | 465 (2701070) | -25.6 | 0.066 | 400 (270–810) | 370 (260–590) | -7.5 | 0.001 | 310 (200–510) | 270 (200–380) | -12.9 | 0.129 | 0.099 |
| CRP mg/L | 0.7 (0.4–1.7) | 0.6 (0.4–2.0) | -9.1 | 0.734 | 0.9 (0.6–1.8) | 0.5 (0.3–1.0) | -50.0 | 0.133 | 0.5 (0.4–1.3) | 0.5 (0.3–2.0) | 10.2 | 0.829 | 0.256 |
| IL6 ng L-1 | 10.1 (7.5–11.7) | 10.9 (8.5–12.4) | 7.9 | 0.211 | 9.6 (7.5–11.3) | 9.3 (7.2–11.0) | -3.1 | 0.380 | 7.5 (6.9–9.6) | 7.4 (6.2–9.9) | -1.3 | 0.041 | 0.090 |
| IL8 ng L-1 | 19.6 (16.4–21.3) | 18.4 (16.4–22.9) | -6.1 | 0.755 | 17.8 (16.6–20.7) | 19.2 (16.0–20.5) | 7.9 | 0.927 | 19.5 (16.6–23.0) | 19.0 (16.6-20.1) | -2.6 | 0.034 | 0.187 |
| IL10 ng L-1 | 17.6 (12.7–21.7) | 17.2 (12.7–25.7) | -2.3 | 0.703 | 16.8 (12.7–25.7) | 15.8 (10.6–21.0) | -6.0 | 0.710 | 14.7 (12.7–15.8) | 14.2 (11.6–16.7) | -3.4 | 0.038 | 0.360 |
| ICAM μg L-1 | 372 (270–506) | 362 (275– 567) | -2.7 | 0.642 | 523 (362–873) | 514 (362–801) | -1.7 | 0.554 | 662 (507–806) | 667 (520–787) | -0.8 | 0.325 | 0.515 |
| Selectin mg L-1 | 27.0 (6.8) | 27.9 (7.9) | 3.3 | 0.140 | 25.4 (4.9) | 25.1 (4.9) | -1.2 | 0.626 | 27.8 (5.6) | 26.9 (5.9) | -4.3 | 0.101 | 0.060 |
| NT-pro-BNP ng L-1 | 707 (401–1604) | 669 (335–1360) | -5.4 | 0.074 | 396 (296–541) | Δ308 (187–394) | -1.2 | 0.001 | 111 (66–221) | 111 (52–297) | -4.3 | 0.681 | 0.007 II–III |
| BMI kg m-2 median (IQR) | 29 (26.5–31.6) | 28.9 (26.9–30.7) | -0.3 | 0.104 | 30 (27.1–32.6) | 29.1 (27.0–31.5) | -3.0 | 0.001 | 29.3 (26.8–30.9) | 29.2 (26.8-32.0) | -0.3 | 0.144 | 0.082 |